Applied Therapeutics (APLT) Peer Comparison

$0.10

$0.00 (0.00%)

As on 04-Feb-2026 09:30EDT

Market cap

$15 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

7.7

Div. Yield

0 %

Edit

	Applied Therapeutics (APLT)	FibroGen (FGEN)	Salarius Pharmaceuticals (SLRX)
Market cap ($ Mln)	15	39	5
Revenue ($ Mln)	1	-118	--
Net Profit ($ Mln)	-18.14	215.65	-5.00
Net Margin (%)	-1,815.62	-182.61	-113,076.32
RoE (%)	--	--	-232.24
Price to Earnings	--	--	--
Price-To-Book	7.72	53.83	1.13

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Applied Therapeutics (APLT)	FibroGen (FGEN)	Salarius Pharmaceuticals (SLRX)
Operating Revenue	1.00	-118.09	0.00
Cost of Revenue	17.76	-20.39	0.01
Gross Profit	-48.29	14.06	0.00
Operating Expenses	81.64	26.33	5.07
Operating Profit (EBIT)	-98.40	-124.04	-5.07
Other Income	0.00	0.00	0.00
Profit before Tax	-18.14	-131.27	-5.00
Provision for Tax	0.12	-213.92	0.00
Profit after Tax (Net Income)	-18.14	215.65	-5.00
Minority Interest	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00

Liabilities ($ Mln)

	Applied Therapeutics (APLT)	FibroGen (FGEN)	Salarius Pharmaceuticals (SLRX)
Shareholder's Funds	-0.56	-17.03	4.25
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	2.03	83.56	0.74
Current Liabilities	32.90	35.97	1.10
Total Liabilities	86.69	214.53	3.02

Assets ($ Mln)

	Applied Therapeutics (APLT)	FibroGen (FGEN)	Salarius Pharmaceuticals (SLRX)
Non-Current Assets	2.72	3.59	0.03
Current Assets	31.65	133.42	6.06
Total Assets	86.69	214.53	3.02
Total Debt*	2.50	19.47	0.00
Net Current Assets	-1.25	97.45	4.22

Cashflow ($ Mln)

	Applied Therapeutics (APLT)	FibroGen (FGEN)	Salarius Pharmaceuticals (SLRX)
Cash From Operating Activities	-84.31	-138.00	-4.53
Cash Flow from Investing Activities	--	125.99	--
Cash from Financing Activities	113.81	-0.26	1.06
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Applied Therapeutics (APLT)	FibroGen (FGEN)	Salarius Pharmaceuticals (SLRX)
ROCE (%)	-486.39	56.26	-152.54
ROE (%)	-529.97	22.14	-232.24
ROA (%)	-13.30	68.69	-78.57
EBIT Margin (%)	-10,073.57	109.06	-114,018.08
Net Margin (%)	-1,815.62	-182.61	-113,076.32
Cash Profit Margin (%)	0.00	0.00	-25.56

Growth Ratios

	Applied Therapeutics (APLT)	FibroGen (FGEN)	Salarius Pharmaceuticals (SLRX)
Revenue Growth (%)	573.46	-218.29	-75.26
EBIT Growth (%)	-9.05	19.64	3.26
Net Profit Growth (%)	90.32	277.07	-0.22
EPS Growth (%)	93.16	677.48	61.93
Book Value Growth (%)	-109.44	93.05	-74.09

Valuation Ratios

	Applied Therapeutics (APLT)	FibroGen (FGEN)	Salarius Pharmaceuticals (SLRX)
Price / Earnings	-1.11	-0.04	-0.02
Price / Book Value	2.06	-0.01	0.08
Dividend Yield (%)	--	--	--
EV/EBITDA	-0.39	-0.29	0.37
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Applied Therapeutics (APLT)	FibroGen (FGEN)	Salarius Pharmaceuticals (SLRX)
Debt to Equity	0.00	0.00	0.00
Short term debt to equity ratio	-0.83	0.00	0.00
Current Ratio	0.96	3.71	5.49
Quick Ratio	0.96	3.60	5.49
Interest Coverage	--	-14.33	--

Operating Efficiency Ratios

	Applied Therapeutics (APLT)	FibroGen (FGEN)	Salarius Pharmaceuticals (SLRX)
Debtors to sales (%)	1,666.97	-0.10	0.00
Asset Turnover	0.01	-0.38	0.00
Receivable days	228.78	256.07	--
Inventory Days	24.60	524.84	--
Payable days	23.14	270.21	63,565.68
Cash Conversion Cycle	230.25	510.70	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly